GLP-1 RA on Alcohol Consumption, Metabolism and Liver Parameters in Patients With Obesity and Fatty Liver Disease
- Status
- Not yet recruitingResults none
- Why it is watched
- non-weight indication: liver, addiction
- Who it enrolls
- age 18 Years to 80 Years; BMI ≥28 required; conditions: Adiposity; Fatty Liver; Alcohol Use Disorder
- Interventions
- Semaglutide; Weight reduction recommendations (nutritional and exercise)
- Conditions
- Adiposity; Fatty Liver; Alcohol Use Disorder
- Phase and size
- NA · 64 participants
- Dates
- Start 2026-11-01
Primary completion 2026-12-31 - Sponsor
- Insel Gruppe AG, University Hospital Bern (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Proportion of patients achieving total alcohol abstinence (measured by negative PEth test)From inclusion date (baseline) until end of the study, total duration 16 weeks per patient
02Eligibility
Who can take part
Inclusion Criteria: * BMI ≥ 35 kg/m² OR BMI ≥ 28 kg/m² in the case of weight-related co-morbidities (pre-diabetes or type 2 diabetes mellitus, hypertension, dyslipidemia). * Fatty liver disease (steatosis on ultrasound and/or CAP value on FS \> 238 dB/m) * Age 18 - 80 years * Alcohol Use Disorder Identification Test-C Score \>4 (AUDIT-C) Score ≥4 for women and ≥5 for men (as measured from AUDIT-questionnaire distributed in visit 1) * Sufficient skills for German or French language (written and spoken) * Signed informed consent Exclusion Criteria: * Active illicit substance use * AUDIT-score \< 5 (males)/ 4 (females) (as measured from AUDIT-questionnaire distributed in visit 1) * Current treatment with drugs against alcohol dependence (disulfiram, acamprosate, naltrexone, baclofen and nalmefene) * Any known contraindication to semaglutide * Presence or history of a hepatic or extrahepatic malignancy from the previous 6 months
03Change log
Registry changes
No changes recorded since the trial was added.